Steve Shivers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steve Shivers has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Anying Zhang
9 shared publications- Chung S. Yang
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, USA
9 shared publications Domenico Coppola
9 shared publicationsKazim Husain
9 shared publicationsAshley Davis-Yadley
8 shared publicationsMokenge P. Malafa
8 shared publications
Latest Publications
- Open Access
- 4 September 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (2) , e152-e158.e1
A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy
- 4 September 2024
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (2) , e152-e158.e1
Open AccessA 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This study evaluated the preclinical activity of δ-tocotrienol (DT3), a bioactive form of vitamin E, in the inhibition of colorectal cancer growth and development in vitro and in vivo. DT3 is the most bioactive isomer of vitamin E in inhibiting growth of colorectal cancer cells. However, it had little effect on the proliferation of normal colon mucosal cells NCM460. In HCT-116 and SW-620 colorectal cancer cells, DT3 (50 μmol/L) significantly inhibited malignant transformation (P < 0.02, P < 0.001), cell migration (P < 0.02, P < 0.05), and invasion (P < 0.05, P < 0.01) compared with vehicle. DT3 inhibited markers for epithelial (E-cadherin) to mesenchymal (vimentin) transition, metastasis (matrix metalloproteinase 9), angiogenesis VEGF, inflammation (NF-κB), and Wnt signaling (β-catenin) compared with vehicle in colorectal cancer cells. DT3 induced apoptosis selectively in colorectal cancer cells (SW-620 cells, HCT-116 cells, and HT-29) without affecting the normal colon cells. In the azoxymethane-induced colorectal carcinogenesis model in rats, DT3 (200 mg/kg orally twice a day) for 20 weeks significantly inhibited colorectal polyps by 70% and colorectal cancer by almost 99% compared with the vehicle treatment group (P < 0.02, P < 0.001), and the cancer inhibition effect was more potent than sulindac (50%). Taken together, these data demonstrate that DT3 is a potential chemopreventive agent in colorectal cancer, warranting further investigation into its clinical use in the prevention and treatment of colorectal cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This study evaluated the preclinical activity of δ-tocotrienol (DT3), a bioactive form of vitamin E, in the inhibition of colorectal cancer growth and development in vitro and in vivo. DT3 is the most bioactive isomer of vitamin E in inhibiting growth of colorectal cancer cells. However, it had little effect on the proliferation of normal colon mucosal cells NCM460. In HCT-116 and SW-620 colorectal cancer cells, DT3 (50 μmol/L) significantly inhibited malignant transformation (P < 0.02, P < 0.001), cell migration (P < 0.02, P < 0.05), and invasion (P < 0.05, P < 0.01) compared with vehicle. DT3 inhibited markers for epithelial (E-cadherin) to mesenchymal (vimentin) transition, metastasis (matrix metalloproteinase 9), angiogenesis VEGF, inflammation (NF-κB), and Wnt signaling (β-catenin) compared with vehicle in colorectal cancer cells. DT3 induced apoptosis selectively in colorectal cancer cells (SW-620 cells, HCT-116 cells, and HT-29) without affecting the normal colon cells. In the azoxymethane-induced colorectal carcinogenesis model in rats, DT3 (200 mg/kg orally twice a day) for 20 weeks significantly inhibited colorectal polyps by 70% and colorectal cancer by almost 99% compared with the vehicle treatment group (P < 0.02, P < 0.001), and the cancer inhibition effect was more potent than sulindac (50%). Taken together, these data demonstrate that DT3 is a potential chemopreventive agent in colorectal cancer, warranting further investigation into its clinical use in the prevention and treatment of colorectal cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This document contains the figure legends for Supplementary Figures 1-5.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This document contains the figure legends for Supplementary Figures 1-5.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This document contains the figure legends for Supplementary Figures 1-5.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This document contains the figure legends for Supplementary Figures 1-5.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This file contains Supplementary Table 1.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This file contains Supplementary Table 1.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This file contains Supplementary Table 1.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This file contains Supplementary Table 1.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This study evaluated the preclinical activity of δ-tocotrienol (DT3), a bioactive form of vitamin E, in the inhibition of colorectal cancer growth and development in vitro and in vivo. DT3 is the most bioactive isomer of vitamin E in inhibiting growth of colorectal cancer cells. However, it had little effect on the proliferation of normal colon mucosal cells NCM460. In HCT-116 and SW-620 colorectal cancer cells, DT3 (50 μmol/L) significantly inhibited malignant transformation (P < 0.02, P < 0.001), cell migration (P < 0.02, P < 0.05), and invasion (P < 0.05, P < 0.01) compared with vehicle. DT3 inhibited markers for epithelial (E-cadherin) to mesenchymal (vimentin) transition, metastasis (matrix metalloproteinase 9), angiogenesis VEGF, inflammation (NF-κB), and Wnt signaling (β-catenin) compared with vehicle in colorectal cancer cells. DT3 induced apoptosis selectively in colorectal cancer cells (SW-620 cells, HCT-116 cells, and HT-29) without affecting the normal colon cells. In the azoxymethane-induced colorectal carcinogenesis model in rats, DT3 (200 mg/kg orally twice a day) for 20 weeks significantly inhibited colorectal polyps by 70% and colorectal cancer by almost 99% compared with the vehicle treatment group (P < 0.02, P < 0.001), and the cancer inhibition effect was more potent than sulindac (50%). Taken together, these data demonstrate that DT3 is a potential chemopreventive agent in colorectal cancer, warranting further investigation into its clinical use in the prevention and treatment of colorectal cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This study evaluated the preclinical activity of δ-tocotrienol (DT3), a bioactive form of vitamin E, in the inhibition of colorectal cancer growth and development in vitro and in vivo. DT3 is the most bioactive isomer of vitamin E in inhibiting growth of colorectal cancer cells. However, it had little effect on the proliferation of normal colon mucosal cells NCM460. In HCT-116 and SW-620 colorectal cancer cells, DT3 (50 μmol/L) significantly inhibited malignant transformation (P < 0.02, P < 0.001), cell migration (P < 0.02, P < 0.05), and invasion (P < 0.05, P < 0.01) compared with vehicle. DT3 inhibited markers for epithelial (E-cadherin) to mesenchymal (vimentin) transition, metastasis (matrix metalloproteinase 9), angiogenesis VEGF, inflammation (NF-κB), and Wnt signaling (β-catenin) compared with vehicle in colorectal cancer cells. DT3 induced apoptosis selectively in colorectal cancer cells (SW-620 cells, HCT-116 cells, and HT-29) without affecting the normal colon cells. In the azoxymethane-induced colorectal carcinogenesis model in rats, DT3 (200 mg/kg orally twice a day) for 20 weeks significantly inhibited colorectal polyps by 70% and colorectal cancer by almost 99% compared with the vehicle treatment group (P < 0.02, P < 0.001), and the cancer inhibition effect was more potent than sulindac (50%). Taken together, these data demonstrate that DT3 is a potential chemopreventive agent in colorectal cancer, warranting further investigation into its clinical use in the prevention and treatment of colorectal cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This PowerPoint contains supplementary figures 1-5.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This PowerPoint contains supplementary figures 1-5.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This PowerPoint contains supplementary figures 1-5.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Chemoprevention of Azoxymethane-induced Colon Carcinogenesis by Delta-Tocotrienol
This PowerPoint contains supplementary figures 1-5.
- Open Access
- 15 September 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 115 (1) , 93-102
A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy
- 15 September 2022
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 115 (1) , 93-102
Open AccessA Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy